PUZZLEPHARM Trademark

Trademark Overview


On Monday, January 22, 2024, a trademark application was filed for PUZZLEPHARM with the United States Patent and Trademark Office. The USPTO has given the PUZZLEPHARM trademark a serial number of 98369635. The federal status of this trademark filing is SUSPENSION LETTER - MAILED as of Saturday, August 24, 2024. This trademark is owned by ND Enterprise, LLC. The PUZZLEPHARM trademark is filed in the Computer & Software Services & Scientific Services category with the following description:

Pharmaceutical products development

General Information


Serial Number98369635
Word MarkPUZZLEPHARM
Filing DateMonday, January 22, 2024
Status653 - SUSPENSION LETTER - MAILED
Status DateSaturday, August 24, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateNOT AVAILABLE

Trademark Statements


Pseudo MarkPUZZLE PHARM
Goods and ServicesPharmaceutical products development

Classification Information


International Class042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateMonday, January 22, 2024
Primary Code042
First Use Anywhere DateTuesday, April 25, 2023
First Use In Commerce DateFriday, September 1, 2023

Trademark Owner History


Party NameND Enterprise, LLC
Party Type10 - Original Applicant
Legal Entity Type16 - Limited Liability Company
AddressNew Milford, CT 06776

Trademark Events


Event DateEvent Description
Monday, January 22, 2024NEW APPLICATION ENTERED
Wednesday, May 22, 2024NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Sunday, August 18, 2024ASSIGNED TO EXAMINER
Saturday, August 24, 2024LETTER OF SUSPENSION E-MAILED
Saturday, August 24, 2024SUSPENSION LETTER WRITTEN
Saturday, August 24, 2024NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Friday, November 22, 2024TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED